Merck received FDA approval to expand Welireg (belzutifan) into a broader set of kidney cancer patients when used in combination with Eisai’s Lenvima (lenvatinib). The new label applies to patients with advanced renal cell carcinoma with a clear cell component. The move extends the commercial reach of Welireg beyond its prior use, positioning the combination strategy as an additional option for patients who may have limited responses to existing standards. It also reinforces the ongoing role of HIF-2α pathway inhibition in RCC treatment. For the biotech ecosystem, label expansion of a blockbuster-adjacent asset can quickly alter competitive dynamics—especially where combination regimens are the key differentiator for payers and sequencing decisions. Merck’s decision reflects how regulators increasingly translate pivotal combination data into earlier or wider clinical positioning as evidence accumulates.